eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
3/2021
vol. 38
 
Share:
Send email
Share:
abstract:
Original paper

The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials

Xiaofen Jin
1
,
Lianfang Wu
2
,
Ji Wang
3
,
Malong Feng
3

  1. Department of Pediatrics, Fenghua District People’s Hospital of Ningbo, Zhejiang, China
  2. Department of Pediatrics, Ningbo Yinzhou Second Hospital, Zhejiang, China
  3. Department of Respiration, Fenghua District People’s Hospital of Ningbo, Zhejiang, China
Adv Dermatol Allergol 2021; XXXVIII (3): 377–383
DOI: https://doi.org/10.5114/ada.2020.92519
Online publish date: 2020/01/31
View full text Get citation
 
Introduction
The comparison of fluticasone propionate/formoterol (FP/FORM) with fluticasone propionate/salmeterol (FP/SAL) for paediatric asthma remains controversial. Aim: We conduct a systematic review and meta-analysis to explore the efficacy and safety of FP/FORM versus FP/SAL for paediatric asthma.

Material and methods
We have searched PubMed, Embase, Web of science, EBSCO, and Cochrane library databases through August 2019 for randomized controlled trials (RCTs) assessing the effect of FP/FORM versus FP/SAL for paediatric asthma. This meta-analysis is performed using the random-effects model.

Results
Three RCTs are included in the meta-analysis. Overall for paediatric asthma, FP/FORM and FP/SAL demonstrate a comparable influence on FEV1 (Std. MD = –0.01; 95% CI: –0.04 to 0.03; p = 0.62), FVC (Std. MD = 0; 95% CI: –0.07 to 0.06; p = 0.87), FEF25 (Std. MD = –1.69; 95% CI: –6.69 to 3.31; p = 0.51), FEF50 (Std. MD = 0.10; 95% CI: –0.12 to 0.33; p = 0.37), FEF75 (Std. MD = 0.01; 95% CI: –0.21 to 0.24; p = 0.91), asthma symptom scores (Std. MD = –0.03; 95% CI: –0.11 to 0.04; p = 0.43), sleep disturbance scores (Std. MD = 0.03; 95% CI: –0.19 to 0.24; p = 0.81) and adverse events (RR = 1.07; 95% CI: 0.83 to 1.38; p = 0.61).

Conclusions
FP/FORM and FP/SAL show a comparable efficacy for paediatric asthma.

keywords:

fluticasone propionate/formoterol, propionate/salmeterol, paediatric asthma, randomized controlled trials, meta-analysis
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.